MIP Discovery Limited

MIP Discovery designs and develops non-biological affinity reagents to accelerate the development and production of cell and gene therapies. Taking the industry beyond the limitations of biological reagents, these synthetic antibody alternatives enable greater insight and control over viral vector characterization and purification, along with contaminant identification and removal.

Cost and complexity of development and manufacture remains a significant barrier to the widespread adoption of cell and gene therapies. The industry needs better tools to improve the speed, safety, and efficiency of manufacturing at scale, making advanced therapies more accessible to patients. Already proven in novel diagnostic applications, MIP Discovery’s synthetic antibody alternatives offer a fresh approach to downstream processing for cell and gene therapy developers.

MIP Discovery is partnering with leading companies in the cell and gene therapy sector to introduce novel synthetic affinity reagents, aligned to critical applications. The Company is backed by leading life sciences investor groups, including Mercia and Calculus Capital.